decisionhealth Newsletters, Answer Books - 2006 Issue 3 (March)
Program_Memos / 2002 / B-02-057
Subscribe or sign in to view the full article.
Article Overview
This article is a 2002 CMS Program Memorandum addressing Medicare carrier and DMERC processing for oral anti-cancer drug billing. It explains the addition of new WW identifiers tied to two etoposide sources, notes the continued use of the appropriate NDC for billing, and provides effective and implementation timing. It is relevant to billing staff, DMERC operations, and Medicare claims processing teams working with pharmaceutical source identification.
Why This Topic Matters
It helps readers recognize a Medicare systems update affecting how a specific oral oncology drug source was identified and processed in 2002, which is useful for historical reference and claims administration context.
What You Will Learn
- The purpose of the CMS program memorandum
- The general billing and processing context for oral anti-cancer drugs
- The timing of the memorandum’s effectiveness and implementation
- The Medicare operational context in which the update was issued
Who Should Read This
- Medical coders
- Billing staff
- DMERC operations staff
- Medicare claims processing teams
- Compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com